EU Extends Review of Teva, Cephalon Deal After Remedies

The European Commission extended its review of Teva Pharmaceutical Industries Ltd.’s bid for Cephalon Inc. after it was offered remedies to allay possible competition concerns over the deal.

The new deadline is Oct. 13, the commission said in a filing on its website today. It didn’t specify the remedies that were offered.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE